drugset / Trial / NCT00254787

Rapid Dose Escalation of Quetiapine Versus Conventional Escalation in Acute Schizophrenic Patients

NCT00254787

Phase 2 Completed 30 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the study is to compare the safety and tolerability of IR (Immediate-Release) quetiapine in a rapid escalation scheme with to the current approved label titration.

Timeline

Start
2005-06
Primary completion
Completion
2006-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Quetiapine Small molecule

Indications